GSK2838232 is primarily investigated for its potential application in the treatment of HIV. It functions as a maturation inhibitor, targeting the virus at a critical stage in its life cycle. By interfering with the processing of viral polyproteins, it prevents the formation of mature, infectious viral particles. This mechanism offers a promising approach to suppress viral replication, particularly in cases where resistance to other antiretroviral therapies has developed. Its application is being explored in combination with other HIV drugs to enhance treatment efficacy and reduce the risk of resistance. Research is ongoing to evaluate its safety, pharmacokinetics, and therapeutic potential in clinical settings.